Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.40 |
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924257 | 0.90 | PPARG (0.45) | PTGESPTGDRPPARG | |
| SCHEMBL4921999 | 0.88 | CHRNA7 (0.42) | PTGDR2 | |
| SCHEMBL4922298 | 0.83 | PTGES (0.40) | PTGDR2PTGESPPARGMCL1 | |
| SCHEMBL4926553 | 0.83 | PTGES (0.41) | PTGDR2PTGESPPARGMCL1 | |
| SCHEMBL4916843 | 0.81 | MAPT (0.47) | PTGESPTGDR | |
| SCHEMBL4922258 | 0.80 | MAPT (0.47) | PTGESPTGDR | |
| SCHEMBL4922669 | 0.78 | PTGDR (0.44) | PTGDR2PTGESPTGDRPPARGMCL1 | |
| SCHEMBL4924264 | 0.77 | PTGES (0.52) | PTGESPPARG | |
| SCHEMBL4926075 | 0.76 | PTGES (0.54) | PTGESPPARG | |
| SCHEMBL4918295 | 0.75 | PTGDR (0.42) | PTGDR2PTGESPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1844013-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077364-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | PTGDR2 119/4885PTGES 35/4885PTGDR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.